Yali Liang

816 total citations
41 papers, 643 citations indexed

About

Yali Liang is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Yali Liang has authored 41 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 11 papers in Oncology and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Yali Liang's work include Diabetes Treatment and Management (9 papers), Metabolism, Diabetes, and Cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Yali Liang is often cited by papers focused on Diabetes Treatment and Management (9 papers), Metabolism, Diabetes, and Cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Yali Liang collaborates with scholars based in United States, China and France. Yali Liang's co-authors include Vaishali Sahasrabudhe, Sara M. Tolaney, Jennifer Dong, Geoffrey I. Shapiro, James M. Cleary, Kathleen Turnbull, Revathi Ananthakrishnan, Jean‐Charles Soria, Antoine Hollebecque and Michelle I. Rossulek and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Yali Liang

39 papers receiving 624 citations

Peers

Countries citing papers authored by Yali Liang

Since Specialization

Citations

This map shows the geographic impact of Yali Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yali Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yali Liang more than expected).

Fields of papers citing papers by Yali Liang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yali Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yali Liang. The network helps show where Yali Liang may publish in the future.

Co-authorship network of co-authors of Yali Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Yali Liang. A scholar is included among the top collaborators of Yali Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yali Liang. Yali Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hyper-Relational Knowledge Enhanced Network for Hypertension Medication Recommendation 2024 ·IEEE Transactions on Computational Social Systems ·(unknown), (unknown), (unknown), Yali Liang, (unknown)	1
2	An efficient state-aware Coarse-Fine-Grained model for Knowledge Tracing 2024 ·Knowledge-Based Systems ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yali Liang	2
3	Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study 2024 ·Blood Advances ·Luke Maese, Mignon L. Loh, Mi Rim Choi, (unknown), Etsuko Aoki, Yali Liang, Tong Lin, Suzette Girgis, Cuiping Chen, Shane Roller, Vijayalakshmi Chandrasekaran, Robert Iannone, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau	0
4	[Sleep patterns of infants and young children and their association with breastfeeding: a study based on K-means clustering]. 2022 ·PubMed ·Yali Liang, (unknown), Yu‐Xiao Zhang, Min Zhang, (unknown), (unknown), (unknown)	0
5	End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor 2021 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Gianluca Nucci, (unknown), Ernesto Callegari, Susan Zhou, Cynthia J. Musante, Yali Liang, Kevin Sweeney, Vaishali Sahasrabudhe	9
6	Systematic Analysis of Impact of Sampling Regions and Storage Methods on Fecal Gut Microbiome and Metabolome Profiles 2020 ·mSphere ·Yali Liang, Tianyu Dong, Minjian Chen, Lianping He, Tingzhang Wang, Xingyin Liu, Hang Chang, Jian‐Hua Mao, Bo Hang, Antoine M. Snijders, Yankai Xia	46
7	Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components 2019 ·Clinical Pharmacology in Drug Development ·(unknown), Kyle Matschke, Yali Liang, (unknown), Hua Wei, Haihong Shi, Almasa Bass, Anne Hickman, Steven G. Terra, Susan Zhou, Rajesh Krishna, Vaishali Sahasrabudhe	4
8	Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects 2018 ·Clinical Therapeutics ·(unknown), Vaishali Sahasrabudhe, Yali Liang, Kyle Matschke, Haihong Shi, Anne Hickman, Didier Saur, Steven G. Terra, David L. Cutler	19
9	Meconium microbiome associates with the development of neonatal jaundice 2018 ·Clinical and Translational Gastroenterology ·Tianyu Dong, (unknown), Richard White, Xu Wang, (unknown), Yali Liang, Yuqing Zhang, Chuncheng Lu, Minjian Chen, Heidi Aase, Yankai Xia	26
10	An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A 2017 ·Clinical Therapeutics ·Hongzhong Liu, Runhui Wu, Pei Hu, Feifei Sun, Lihong Xu, Yali Liang, Sunil Nepal, Peng Qu, (unknown), Joan Korth‐Bradley	2
11	Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers 2017 ·Cancer Chemotherapy and Pharmacology ·Nagdeep Giri, Lisa H. Lam, Robert R. LaBadie, Joseph F. Krzyzaniak, (unknown), Brian Hee, Yali Liang, M. Naveed Shaik	12
12	Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects 2016 ·Clinical Therapeutics ·(unknown), Sanela Tarabar, Yali Liang, Vivek Pradhan, Jane G. Owens, Barry S. Oemar	24
13	Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example 2016 ·Pharmaceutical Research ·Marci L. Chew, Joyce Mordenti, (unknown), (unknown), Ruolun Qiu, Juanzhi Fang, Yali Liang, Brian Corrigan	3
14	The understanding, attitude and use of nutrition label among consumers (China). 2015 ·PubMed ·(unknown), (unknown), (unknown), Yu Zhu, Haibo Li, Yufeng Wen, Hui Yuan, Yali Liang	27
15	Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers 2015 ·The Journal of Clinical Pharmacology ·Ana Ruiz-Garcı́a, Joanna C. Masters, (unknown), Robert R. LaBadie, Yali Liang, (unknown), (unknown), (unknown), Zelanna Goldberg, Carlo L. Bello	20
16	Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib 2015 ·Investigational New Drugs ·Nagdeep Giri, Joanna C. Masters, Anna Plotka, Yali Liang, (unknown), P. Gómez Pardo, Joseph O’Connell, Carlo L. Bello	19
17	Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis. 2014 ·PubMed ·Yali Liang, Lianping He, Hui Yuan, Yuelong Jin, Yingshui Yao	8
18	Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: A pharmacokinetic, safety and tolerability study 2013 ·Growth Hormone & IGF Research ·(unknown), Robert R. LaBadie, Yali Liang, (unknown), Xiang Gao, J. Hey‐Hadavi	2
19	Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib. 2013 ·Journal of Clinical Oncology ·Nagdeep Giri, Anna Plotka, Yali Liang, (unknown), (unknown), Joanna C. Masters, Michael DeMicco, P. Gómez Pardo, Carlo L. Bello, Joseph O’Connell	2
20	[Prevalence of suicide ideation among middle school students in China: a systematic analysis of studies between 2000 and 2012]. 2013 ·PubMed ·Weiwei Chang, Yingshui Yao, Hui Yuan, Baifeng Chen, Yali Liang, Yan Chen, (unknown), Jiang Li, Yu Zhu	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact